Ruzicka 1998.

Methods	DESIGN Between‐patient Participant delivery ALLOCATION Random Method of randomisation: not stated Concealment: unclear BLINDING Double‐blind (participant/assessor) WITHDRAWAL/DROPOUT Described
Participants	N: 178 Treatment duration: 2 + 4 wks; FU: 14 wks LF: 7 (3.9%) BC: psoriasis comparable, demographics not reported Age: 42 (range = 18 to 80) Gender (per cent men): 55.6% Severity: PASI = 6.0 INCLUSION CRITERIA Adults Chronic plaque‐type psoriasis BSA ≥ 30% Calcium levels, renal, and liver function within normal range EXCLUSION CRITERIA Pregnancy Lactation Recent systemic or UV therapy
Interventions	Calcipotriol 0.005% ointment BD 6 weeks (C) Calcipotriol 0.005% ointment BD 2 weeks, then calcipotriol ointment 0.005% OM plus Betamethasone valerate ointment ON 4 weeks (CB)
Outcomes	PASI Investigator Global Assessment (6‐pt: deterioration to complete healing) Patient evaluation of overall response (5‐pt: scale NR)
Notes	The trial did not state sponsorship. Schering AG employed 1 author.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	The trial reported insufficient details.
Blinding (performance bias and detection bias) All outcomes	Low risk	The trial was double‐blind (participant/investigator).
Randomisation method reported	Unclear risk	The trial did not report this.
Loss to follow up	Low risk	3.9%
Baseline assessments	Low risk	These were partially done.
Baseline comparability demonstrated	Unclear risk	This was partially demonstrated.